vs
CG Oncology, Inc.（CGON）与Revolution Medicines, Inc.（RVMD）财务数据对比。点击上方公司名可切换其他公司
CG Oncology, Inc.自由现金流更多（$-36.2M vs $-139.5M）
CG Oncology是一家临床阶段生物技术企业，专注于开发针对泌尿生殖系统癌症的创新靶向免疫疗法，核心适应症包括非肌层浸润性膀胱癌，主要面向美国市场推进管线候选药物研发，以满足相关未被满足的临床需求。
Tempus AI是美国健康科技企业，2015年由埃里克·莱夫科夫斯基在伊利诺伊州芝加哥创立，成立契机为其妻子确诊乳腺癌。公司依托数据与人工智能技术，为肿瘤、心脏病、放射医学、抑郁症等领域提供包含诊断在内的精准医疗服务，2024年6月14日于纳斯达克上市，股票代码为TEM。
CGON vs RVMD — 直观对比
营收规模更大
CGON
是对方的Infinity倍
$0
自由现金流更多
CGON
多$103.3M
$-139.5M
损益表 — Q4 FY2025 vs Q4 FY2024
| 指标 | | |
|---|---|---|
| 营收 | $2.3M | $0 |
| 净利润 | $-41.3M | $-194.6M |
| 毛利率 | — | — |
| 营业利润率 | -2097.3% | — |
| 净利率 | -1779.0% | — |
| 营收同比 | 409.2% | — |
| 净利润同比 | -29.9% | -20.4% |
| 每股收益（稀释后） | $-0.52 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CGONRVMD
| Q4 25 | $2.3M | — | ||
| Q3 25 | $1.7M | — | ||
| Q2 25 | $0 | — | ||
| Q4 24 | $456.0K | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | $529.0K | $0 | ||
| Q3 23 | — | $0 |
净利润CGONRVMD
| Q4 25 | $-41.3M | — | ||
| Q3 25 | $-43.8M | — | ||
| Q2 25 | $-41.4M | — | ||
| Q4 24 | $-31.8M | $-194.6M | ||
| Q3 24 | — | $-156.3M | ||
| Q2 24 | — | $-133.2M | ||
| Q1 24 | $-16.9M | $-116.0M | ||
| Q3 23 | — | $-108.4M |
营业利润率CGONRVMD
| Q4 25 | -2097.3% | — | ||
| Q3 25 | -3069.0% | — | ||
| Q2 25 | — | — | ||
| Q4 24 | -8344.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -4247.4% | — | ||
| Q3 23 | — | — |
净利率CGONRVMD
| Q4 25 | -1779.0% | — | ||
| Q3 25 | -2629.5% | — | ||
| Q2 25 | — | — | ||
| Q4 24 | -6973.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -3200.8% | — | ||
| Q3 23 | — | — |
每股收益（稀释后）CGONRVMD
| Q4 25 | $-0.52 | — | ||
| Q3 25 | $-0.57 | — | ||
| Q2 25 | $-0.54 | — | ||
| Q4 24 | $-0.47 | $-1.13 | ||
| Q3 24 | — | $-0.94 | ||
| Q2 24 | — | $-0.81 | ||
| Q1 24 | $-0.36 | $-0.70 | ||
| Q3 23 | — | $-0.99 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $742.2M | $2.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $752.6M | $2.3B |
| 总资产 | $791.6M | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CGONRVMD
| Q4 25 | $742.2M | — | ||
| Q3 25 | $680.3M | — | ||
| Q2 25 | $661.1M | — | ||
| Q4 24 | $742.0M | $2.3B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | $566.5M | $1.7B | ||
| Q3 23 | — | $813.2M |
股东权益CGONRVMD
| Q4 25 | $752.6M | — | ||
| Q3 25 | $687.6M | — | ||
| Q2 25 | $670.4M | — | ||
| Q4 24 | $733.4M | $2.3B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | $568.9M | $1.7B | ||
| Q3 23 | — | $837.5M |
总资产CGONRVMD
| Q4 25 | $791.6M | — | ||
| Q3 25 | $729.9M | — | ||
| Q2 25 | $701.4M | — | ||
| Q4 24 | $754.8M | $2.6B | ||
| Q3 24 | — | $1.8B | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | $579.1M | $1.9B | ||
| Q3 23 | — | $984.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-36.2M | $-138.3M |
| 自由现金流经营现金流 - 资本支出 | $-36.2M | $-139.5M |
| 自由现金流率自由现金流/营收 | -1560.0% | — |
| 资本支出强度资本支出/营收 | 0.3% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-124.1M | $-567.7M |
8季度趋势，按日历期对齐
经营现金流CGONRVMD
| Q4 25 | $-36.2M | — | ||
| Q3 25 | $-38.9M | — | ||
| Q2 25 | $-28.0M | — | ||
| Q4 24 | $-20.7M | $-138.3M | ||
| Q3 24 | — | $-130.4M | ||
| Q2 24 | — | $-128.2M | ||
| Q1 24 | $-26.0M | $-160.6M | ||
| Q3 23 | — | $-100.5M |
自由现金流CGONRVMD
| Q4 25 | $-36.2M | — | ||
| Q3 25 | $-39.0M | — | ||
| Q2 25 | $-28.0M | — | ||
| Q4 24 | $-20.9M | $-139.5M | ||
| Q3 24 | — | $-133.9M | ||
| Q2 24 | — | $-130.6M | ||
| Q1 24 | $-26.0M | $-163.7M | ||
| Q3 23 | — | $-103.0M |
自由现金流率CGONRVMD
| Q4 25 | -1560.0% | — | ||
| Q3 25 | -2340.4% | — | ||
| Q2 25 | — | — | ||
| Q4 24 | -4577.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -4919.5% | — | ||
| Q3 23 | — | — |
资本支出强度CGONRVMD
| Q4 25 | 0.3% | — | ||
| Q3 25 | 5.8% | — | ||
| Q2 25 | — | — | ||
| Q4 24 | 45.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.3% | — | ||
| Q3 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
